In the latest quarter, 11 analysts provided ratings for Nevro (NYSE:NVRO), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the ...
Following strong financial results revealed last month, US-headquartered Globus Medical has agreed to acquire spinal cord stimulation (SCS) company Nevro for $250m to reinforce its position in the ...
In the last three months, 6 analysts have published ratings on Nevro (NYSE:NVRO), offering a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of their recent ...
The Food and Drug Administration (FDA) has approved the Senza Omnia Spinal Cord Stimulation (SCS) System (Nevro) for the treatment of chronic intractable pain of the trunk and/or limbs. The Omnia SCS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results